問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


CHANGHUA CHRISTIAN HOSPITAL (在職)

Division of Cardiovascular Diseases

Division of Cardiovascular Diseases

Division of Endocrinology

更新時間：2023-09-19

夏建勳
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

11Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

夏建勳

List

30Cases

2009-07-01 - 2010-06-30

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2021-03-31 - 2027-06-30

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Recruiting15Sites

2021-01-01 - 2025-06-30

Phase III

Active
A Phase 3, Randomized, Open-label, Multi-country Study to Evaluate the Immunogenicity, Safety, Reactogenicity and Persistence of a Single Dose of the RSVPreF3 OA Investigational Vaccine and Different Revaccination Schedules in Adults Aged 60 Years and Above

  • Condition/Disease

    Respiratory Syncytial Virus Infections

  • Test Drug

    RSVPreF3 OA investigational vaccine

Participate Sites
7Sites

Recruiting5Sites

Terminated2Sites

2015-05-01 - 2021-05-01

Phase IV

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2023-10-02 - 2030-09-30

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2021-12-10 - 2025-10-31

Phase III

Completed
A Pivotal Phase 3 Randomized, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of the sGC Stimulator Vericiguat/MK-1242 in Adults With Chronic Heart Failure With Reduced Ejection Fraction

  • Condition/Disease

    Chronic Heart Failure With Reduced Ejection Fraction

  • Test Drug

    MK-1242 (vericiguat)

Participate Sites
6Sites

Recruiting6Sites

2023-07-01 - 2026-01-31

Phase III

Completed
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Hypercholesterolemia

  • Condition/Disease

    Hypercholesterolemia、 Familial Hypercholesterolemia

  • Test Drug

    MK-0616

Participate Sites
7Sites

Recruiting7Sites

2024-05-01 - 2029-12-31

Phase III

Active
A Phase 3, Open-label Extension Study to Evaluate the Safety and Efficacy of MK-0616 in Adults With Hypercholesterolemia

  • Condition/Disease

    Hypercholesterolemia

  • Test Drug

    tablet

Participate Sites
10Sites

Recruiting10Sites

2012-12-01 - 2019-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2009-04-01 - 2010-02-01

Phase II

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

1 2 3
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB